Courtesy of Benzinga.
In a report published Monday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Esperion Therapeutics Inc (NASDAQ: ESPR), and raised the price target from $53.00 to $75.00.
In the report, JMP Securities noted, “The completion of two-year carcinogenicity studies represents a key de-risking milestone for ETC-1002; reiterate our Market Outperform rating and increase our price target from $53 to $75 on Esperion Therapeutics. In our view, there is minimal risk of negative results from the two-year carcinogenicity studies for ETC-1002. Specifically, we believe management received final reports for these studies in 4Q14 and we gain confidence from the lack of disclosure of any unexpected negative findings. We see surpassing this milestone as a key de-risking event for the development of ETC-1002 and look to additional value-driving clinical and regulatory catalysts for the drug candidate in 1H15. We believe these catalysts have the potential to further reinforce the strategic attractiveness of the asset (either in a large pharma partnership or acquisition of the company). Our $75 price target is derived from a risk-adjusted, NPV analysis of ETC-1002.”
Esperion Therapeutics closed on Friday at $41.23.
Latest Ratings for ESPR
Date | Firm | Action | From | To |
---|---|---|---|---|
Dec 2014 | Credit Suisse | Maintains | Outperform | |
Oct 2014 | Citigroup | Maintains | Buy | |
Oct 2014 | Credit Suisse | Maintains | Outperform |
View More Analyst Ratings for ESPR
View the Latest Analyst Ratings
Posted-In: Jason N. Butler JMP SecuritiesAnalyst Color Price Target Analyst Ratings